|
Renovorx, Inc. (RNXT) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
RenovoRx, Inc. (RNXT) Bundle
¡Evalúe la perspectiva financiera de Renovorx, Inc. (RNXT) como un experto! Esta calculadora DCF (RNXT) proporciona datos financieros preconsados junto con la flexibilidad para modificar el crecimiento de los ingresos, WACC, los márgenes y otros supuestos esenciales para alinearse con sus proyecciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | .0 | -5.7 | -9.9 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 3.9 | 3.2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -3.9 | -3.2 | -5.7 | -10.0 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 2.1 | 1.8 | 15.2 | 6.4 | 1.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .5 | .2 | .5 | .5 | .6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -3.8 | -3.7 | -6.4 | -9.8 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .6 | -.9 | -6.0 | -9.8 | -11.4 | -.6 | .0 | .0 | .0 | .0 |
| WACC, % | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | 1 | |||||||||
| Diluted Shares Outstanding, MM | 10 | |||||||||
| Equity Value Per Share | 0.06 |
What You Will Get
- Comprehensive RNXT Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess RenovoRx's future performance.
- User-Friendly Design: Designed for industry professionals while remaining approachable for newcomers.
Key Features
- Customizable Treatment Parameters: Adjust essential inputs like treatment efficacy, patient demographics, and operational costs.
- Instant Efficacy Analysis: Provides real-time assessments of treatment outcomes and cost-effectiveness.
- High-Precision Results: Utilizes RenovoRx’s proprietary data for accurate treatment valuations.
- Streamlined Scenario Testing: Easily evaluate various treatment scenarios and analyze their impacts.
- Efficiency Booster: Avoid the hassle of developing intricate treatment models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered RenovoRx, Inc. (RNXT) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for RenovoRx, Inc. (RNXT)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose RenovoRx, Inc. (RNXT) Calculator?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses all in one platform.
- Customizable Inputs: Modify the highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes RenovoRx’s intrinsic value and Net Present Value.
- Preloaded Data: Access to historical and projected data for reliable analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants in the healthcare sector.
Who Should Use This Product?
- Investors: Accurately assess RenovoRx’s fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to RenovoRx (RNXT).
- Consultants: Efficiently customize the template for valuation reports tailored to RenovoRx (RNXT) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to the biotech sector.
What the Template Contains
- Preloaded RNXT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.